NYSEMKT: KAPA
Kairos Pharma Ltd Stock Ownership - Who owns Kairos Pharma?

Insider buying vs selling

Have Kairos Pharma Ltd insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Ramachandran MuraliVP of Research and Development2024-11-25200$1.59
$318.00Buy
Doug SamuelsonChief Financial Officer2024-11-222,500$1.50
$3.75kBuy
John S. YuCEO and Chairman2024-11-204,000$1.44
$5.76kBuy

1 of 1

KAPA insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when KAPA insiders and whales buy or sell their stock.

KAPA Shareholders

What type of owners hold Kairos Pharma Ltd stock?

Institutional
Insider
Retail
NameHoldSharesValueType
John S. Yu31.79%5,355,838$2.79MInsider
Armistice Capital LLC8.33%1,404,000$730.08kInstitution
Neil Bhowmick6.77%1,139,983$592.79kInsider
Ramachandran Murali0.87%147,057$76.47kInsider
Doug Samuelson0.36%60,796$31.61kInsider
Scientech Research LLC0.29%48,198$25.06kInstitution
Aptus Capital Advisors LLC0.26%44,286$23.03kInstitution
Hyun W. Bae0.26%44,286$23.03kInsider
Sevenbridge Financial Group LLC0.26%44,286$23.03kInstitution
Rahul Singhvi0.18%30,120$15.66kInsider

1 of 2

KAPA vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
KAPA9.36%40.23%Net Buying
BCLI2.90%97.10%Net Selling
DWTX4.29%64.86%
QNRX1.95%7.08%Net Buying
ADXN0.01%0.00%

Kairos Pharma Stock Ownership FAQ

Who owns Kairos Pharma?

Kairos Pharma (NYSEMKT: KAPA) is owned by 9.36% institutional shareholders, 40.23% Kairos Pharma insiders, and 50.41% retail investors. John S. Yu is the largest individual Kairos Pharma shareholder, owning 5.36M shares representing 31.79% of the company. John S. Yu's Kairos Pharma shares are currently valued at $2.79M.

If you're new to stock investing, here's how to buy Kairos Pharma stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.